When Japan’s Agency for Medical R&D (AMED) was established in March 2015, its over-arching aim was to better coordinate and more efficiently allocate budgets for health-related research spread between the three founding ministries.
Some three and a half years later, there has been progress – particularly in the area of rare disease-related genomic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?